{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:56:43Z","timestamp":1793120203437,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Serotonergic psychedelics are increasingly investigated as treatments for affective disorders. Concerns persist regarding their potential to induce hypomania or mania, particularly in individuals with bipolar spectrum vulnerability. Whether these substances precipitate transient mood switches or contribute to persistent bipolar illness or diagnostic transition remains unclear. We conducted a systematic review of human studies examining manic or hypomanic symptoms following exposure to serotonergic psychedelics (psilocybin, LSD, mescaline, DMT\/ayahuasca) or MDMA (CRD420251160656). Databases and trial registries were searched through January 26, 2026. Eligible designs included randomized and non-randomized clinical studies, registry-based cohorts, cross-sectional surveys, and longitudinal observational studies. Outcomes included dysphoria\/euphoria, manic or hypomanic symptoms and transition to bipolar disorder. Risk of bias was assessed using ROBINS-I, ROB2 or NIH tools. Twenty-three studies met inclusion criteria, four contributing to meta-analysis. Rates of psychedelic-associated dysphoria\/euphoria, hypomania or mania ranged from 5.8% in controlled trials of psilocybin-assisted psychotherapy for major depressive disorders to 30% in naturalistic studies of individuals with bipolar disorder. When present, manic symptoms were typically acute and self-limited. Observational studies identified higher risks among individuals with bipolar I disorder, familial vulnerability, polysubstance use, and unsupervised or illegal use. Registry-based cohorts examining diagnostic transitions showed a prevalence of subsequent transition to bipolar disorder of 4% (95% CI 2\u20138%; N\u2009=\u20097478; I\u00b2\u2009=\u200932.1%), with little evidence for a hallucinogen-specific signal. Overall, serotonergic psychedelics appear to pose a low but clinically meaningful relative risk of transient mood-related symptoms in susceptible individuals while remaining relatively safe in controlled clinical settings. Long-term outcomes and repeated exposure remain insufficiently studied, underscoring the need for rigorous longitudinal research.<\/jats:p>","DOI":"10.1038\/s41380-026-03657-6","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:34:54Z","timestamp":1780068894000},"page":"5749-5763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psychedelic-induced hypomania and mania: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"31","author":[{"given":"Mickael","family":"Eskinazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Nasserdine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romane M.","family":"Cusin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Baniotoupoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi F.","family":"Saccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"De Pieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Corino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Seragnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Briefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Aboulafia Brakha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0778-3728","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Richard-Lepouriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1379-0243","authenticated-orcid":false,"given":"Louise","family":"Penzenstadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerem","family":"B\u00f6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Zullino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-5203","authenticated-orcid":false,"given":"Mikkel","family":"H\u00f8jlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5067-2436","authenticated-orcid":false,"given":"Jacopo","family":"Sapienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2759","authenticated-orcid":false,"given":"Marta","family":"Bosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-7904","authenticated-orcid":false,"given":"Ana","family":"Catalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-5596","authenticated-orcid":false,"given":"Michel","family":"Sab\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"3657_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euroneuro.2022.09.004","volume":"64","author":"M Solmi","year":"2022","unstructured":"Solmi M, Chen C, Daure C, Buot A, Ljuslin M, Verroust V, et al. A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2022;64:44\u201360.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"3657_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","volume":"76","author":"N Perez","year":"2023","unstructured":"Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, et al. Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol. 2023;76:61\u201376.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3657_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2025.105525","volume":"4","author":"ME Liechti","year":"2025","unstructured":"Liechti ME, Gasser P, Aicher HD, Mueller F, Hawrot T, Schmid Y. Implementing psychedelic-assisted therapy: history and characteristics of the Swiss limited medical use program. Neurosci Appl. 2025;4:105525.","journal-title":"Neurosci Appl"},{"key":"3657_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41380-024-02800-5","volume":"30","author":"M Sab\u00e9","year":"2025","unstructured":"Sab\u00e9 M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry. 2025;30:1223\u201355. https:\/\/doi.org\/10.1038\/s41380-024-02800-5.","journal-title":"Mol Psychiatry"},{"key":"3657_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.euroneuro.2025.09.011","volume":"101","author":"M H\u00f8jlund","year":"2025","unstructured":"H\u00f8jlund M, Kafali HY, K\u0131rm\u0131z\u0131 B, Fusar-Poli P, Correll CU, Cortese S, et al. Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: a living systematic review with meta-analysis. Eur Neuropsychopharmacol. 2025;101:41\u201355.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3657_CR6","doi-asserted-by":"publisher","first-page":"103413","DOI":"10.1016\/j.eclinm.2025.103413","volume":"87","author":"V Oliva","year":"2025","unstructured":"Oliva V, De Prisco M, La Spina E, Paolucci S, Fico G, Anmella G, et al. Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials. EClinicalMedicine. 2025;87:103413.","journal-title":"EClinicalMedicine"},{"key":"3657_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S2215-0366(24)00411-5","volume":"12","author":"C Ermis","year":"2025","unstructured":"Ermis C, Taipale H, Tanskanen A, Vieta E, Correll CU, Mittendorfer-Rutz E, et al. Real-world effectiveness of pharmacological maintenance treatment of bipolar depression: a within-subject analysis in a Swedish nationwide cohort. Lancet Psychiatry. 2025;12:198\u2013207.","journal-title":"Lancet Psychiatry"},{"key":"3657_CR8","volume":"6","author":"DE Gard","year":"2021","unstructured":"Gard DE, Pleet MM, Bradley ER, Penn AD, Gallenstein ML, Riley LS, et al. Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies. J Affect Disord Rep. 2021;6:100240.","journal-title":"J Affect Disord Rep"},{"key":"3657_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-022-00265-5","volume":"10","author":"OG Bosch","year":"2022","unstructured":"Bosch OG, Halm S, Seifritz E. Psychedelics in the treatment of unipolar and bipolar depression. Int J Bipolar Disord. 2022;10:18.","journal-title":"Int J Bipolar Disord"},{"key":"3657_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/02698811221131997","volume":"37","author":"E Morton","year":"2022","unstructured":"Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of \u2018magic mushroom\u2019 consumption. J Psychopharmacol. 2022;37:49\u201360.","journal-title":"J Psychopharmacol"},{"key":"3657_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jad.2024.12.044","volume":"373","author":"TD Meyer","year":"2025","unstructured":"Meyer TD, Ibrahim M, Vale LN, Soares JC. Psychedelic use and bipolar disorder - an investigation of recreational use and its impact on mental health. J Affect Disord. 2025;373:505\u201311.","journal-title":"J Affect Disord"},{"key":"3657_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.biopsych.2025.02.903","volume":"98","author":"J Repple","year":"2025","unstructured":"Repple J, Bayas M, M\u00f6ser C, Kobayashi NF, Reif A. Current evidence for the role of rapid-acting antidepressants in bipolar depression: a perspective and plan for action. Biol Psychiatry. 2025;98:333\u201342.","journal-title":"Biol Psychiatry"},{"key":"3657_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/psymed.2023.0051","volume":"2","author":"AE Downey","year":"2024","unstructured":"Downey AE, Bradley ER, Lerche AS, O\u2019Donovan A, Krystal AD, Woolley J. A plea for nuance: should people with a family history of bipolar disorder be excluded from clinical trials of psilocybin therapy? Psychedelic Med. 2024;2:61\u201373.","journal-title":"Psychedelic Med"},{"key":"3657_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177:391\u2013410.","journal-title":"Am J Psychiatry"},{"key":"3657_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.120485","volume":"394","author":"A Do","year":"2026","unstructured":"Do A, Cloutier L, H\u00e9bert-Tremblay L, Thauvin C. Psilocybin use in bipolar disorder: a comprehensive review. J Affect Disord. 2026;394:120485.","journal-title":"J Affect Disord"},{"key":"3657_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","volume":"81","author":"ST Aaronson","year":"2023","unstructured":"Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, et al. Single-Dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type ii major depressive episodes: a nonrandomized controlled trial. JAMA Psychiatry. 2023;81:555\u201362. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4685.","journal-title":"JAMA Psychiatry"},{"key":"3657_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"3657_CR18","unstructured":"National Institutes of Health, National Heart, Lung, and Blood Institute. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. Bethesda, MD: National Heart, Lung, and Blood Institute; 2014."},{"key":"3657_CR19","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"3657_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3657_CR21","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford: Oxford Centre for Evidence-Based Medicine; 2011. Available from: Oxford Centre for Evidence-Based Medicine website."},{"key":"3657_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"3657_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jad.2024.01.197","volume":"351","author":"L Honk","year":"2024","unstructured":"Honk L, Stenfors CUD, Goldberg SB, Hendricks PS, Osika W, Dourron HM, et al. Longitudinal associations between psychedelic use and psychotic symptoms in the United States and United Kingdom. J Affect Disord. 2024;351:194\u2013201. https:\/\/doi.org\/10.1016\/j.jad.2024.01.197.","journal-title":"J Affect Disord"},{"key":"3657_CR24","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291725000716","volume":"55","author":"O Simonsson","year":"2025","unstructured":"Simonsson O, Goldberg SB, Osika W, Stenfors CUD, Chaturvedi S, Swords CM, et al. Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. Psychol Med. 2025;55:e99.","journal-title":"Psychol Med"},{"key":"3657_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/02698811241232548","volume":"38","author":"A Marrocu","year":"2024","unstructured":"Marrocu A, Kettner H, Weiss B, Zeifman RJ, Erritzoe D, Carhart-Harris RL. Psychiatric risks for worsened mental health after psychedelic use. J Psychopharmacol. 2024;38:225\u201335.","journal-title":"J Psychopharmacol"},{"key":"3657_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119857","volume":"390","author":"O Simonsson","year":"2025","unstructured":"Simonsson O, Hendricks PS, Swords CM, Osika W, Goldberg SB. Naturalistic psychedelic use and changes in depressive symptoms. J Affect Disord. 2025;390:119857.","journal-title":"J Affect Disord"},{"key":"3657_CR27","doi-asserted-by":"publisher","first-page":"e0279073","DOI":"10.1371\/journal.pone.0279073","volume":"17","author":"M DellaCrosse","year":"2022","unstructured":"DellaCrosse M, Pleet M, Morton E, Ashtari A, Sakai K, Woolley J, et al. \u2018A sense of the bigger picture:\u2019 A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. PLoS One. 2022;17:e0279073.","journal-title":"PLoS One"},{"key":"3657_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.120437","volume":"394","author":"LN Vale","year":"2026","unstructured":"Vale LN, Ibrahim M, F\u00e1varo-Pereira L, Soares JC, Meyer TD. Contemplating versus having used psychedelics in bipolar disorder - what makes the difference? J Affect Disord. 2026;394:120437.","journal-title":"J Affect Disord"},{"key":"3657_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","volume":"81","author":"ST Aaronson","year":"2024","unstructured":"Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, et al. Single-Dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial. JAMA Psychiatry. 2024;81:555\u201362.","journal-title":"JAMA Psychiatry"},{"key":"3657_CR30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","volume":"5","author":"JD Rosenblat","year":"2024","unstructured":"Rosenblat JD, Meshkat S, Doyle Z, Kaczmarek E, Brudner RM, Kratiuk K, et al. Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin. Med. 2024;5:190\u2013200.e5.","journal-title":"Med"},{"key":"3657_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/psymed.2024.0032","volume":"3","author":"S Meshkat","year":"2025","unstructured":"Meshkat S, Kaczmarek E, Doyle Z, Brudner RM, Gomes FA, Blainey MG, et al. Psilocybin-Assisted psychotherapy for treatment-resistant depression in bipolar II disorder. Psychedelic Med. 2025;3:53\u201358.","journal-title":"Psychedelic Med"},{"key":"3657_CR32","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-Dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"3657_CR33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79:953\u201362.","journal-title":"JAMA Psychiatry"},{"key":"3657_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.encep.2024.06.008","volume":"51","author":"N Wirowski","year":"2025","unstructured":"Wirowski N, Lobato AS, Bender LV, Cardoso TA, Mondin TC, Souza LDM, et al. Serum biomarkers, lifetime substance use and conversion to bipolar disorder. Encephale. 2025;51:383\u20139.","journal-title":"Encephale"},{"key":"3657_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1176\/appi.ajp.22010076","volume":"180","author":"EB Rognli","year":"2023","unstructured":"Rognli EB, Heiberg IH, Jacobsen BK, H\u00f8ye A, Bramness JG. Transition from substance-induced psychosis to schizophrenia spectrum disorder or bipolar disorder. Am J Psychiatry. 2023;180:437\u201344.","journal-title":"Am J Psychiatry"},{"key":"3657_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1176\/appi.ajp.2017.17020223","volume":"175","author":"MSK Starzer","year":"2018","unstructured":"Starzer MSK, Nordentoft M, Hjorth\u00f8j C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 2018;175:343\u201350.","journal-title":"Am J Psychiatry"},{"key":"3657_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamapsychiatry.2024.3532","volume":"82","author":"DT Myran","year":"2025","unstructured":"Myran DT, Pugliese M, Xiao J, Kaster TS, Husain MI, Anderson KK, et al. Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder. JAMA Psychiatry. 2025;82:142\u201350.","journal-title":"JAMA Psychiatry"},{"key":"3657_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF03259908","volume":"4","author":"DL Sultzer","year":"1989","unstructured":"Sultzer DL, Cummings JL. Drug-induced mania-causative agents, clinical characteristics and management. a retrospective analysis of the literature. Med Toxicol Adverse Drug Exp. 1989;4:127\u201343.","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"3657_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jamapsychiatry.2024.0047","volume":"81","author":"O Simonsson","year":"2024","unstructured":"Simonsson O, Mosing MA, Osika W, Ull\u00e9n F, Larsson H, Lu Y, et al. Adolescent psychedelic use and psychotic or manic symptoms. JAMA Psychiatry. 2024;81:579\u201385.","journal-title":"JAMA Psychiatry"},{"key":"3657_CR40","doi-asserted-by":"publisher","first-page":"e1004805","DOI":"10.1371\/journal.pmed.1004805","volume":"22","author":"DT Myran","year":"2025","unstructured":"Myran DT, MacDonald-Spracklin R, Pugliese M, Gibb M, Fiedorowicz JG, Kaster TS, et al. Hospital-based care for hallucinogens and risk of mania and bipolar disorder: a population-based cohort study. PLOS Med. 2025;22:e1004805.","journal-title":"PLOS Med"},{"key":"3657_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/schbul\/sbz102","volume":"46","author":"B Murrie","year":"2020","unstructured":"Murrie B, Lappin J, Large M, Sara G. Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2020;46:505\u201316.","journal-title":"Schizophr Bull"},{"key":"3657_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.schres.2024.03.037","volume":"267","author":"J Cohen-Laroque","year":"2024","unstructured":"Cohen-Laroque J, Grangier I, Perez N, Kirschner M, Kaiser S, Sab\u00e9 M. Positive and negative symptoms in methamphetamine-induced psychosis compared to schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2024;267:182\u201390.","journal-title":"Schizophr Res"},{"key":"3657_CR43","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00213-023-06478-5","volume":"242","author":"O Simonsson","year":"2025","unstructured":"Simonsson O, Goldberg SB, Chambers R, Osika W, Simonsson C, Hendricks PS. Psychedelic use and psychiatric risks. Psychopharmacology. 2025;242:1577\u201383.","journal-title":"Psychopharmacology"},{"key":"3657_CR44","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2019.18","volume":"63","author":"N Andrade-Gonz\u00e1lez","year":"2020","unstructured":"Andrade-Gonz\u00e1lez N, \u00c1lvarez-Cadenas L, Saiz-Ruiz J, Lahera G. Initial and relapse prodromes in adult patients with episodes of bipolar disorder: a systematic review. Eur Psychiatry. 2020;63:e12.","journal-title":"Eur Psychiatry"},{"key":"3657_CR45","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.neubiorev.2007.04.003","volume":"31","author":"RM Post","year":"2007","unstructured":"Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev. 2007;31:858\u201373.","journal-title":"Neurosci Biobehav Rev"},{"key":"3657_CR46","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/0269881119857204","volume":"33","author":"KP Kuypers","year":"2019","unstructured":"Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, et al. Microdosing psychedelics: more questions than answers? An overview and suggestions for future research. J Psychopharmacol. 2019;33:1039\u201357.","journal-title":"J Psychopharmacol"},{"key":"3657_CR47","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/mp.2017.16","volume":"22","author":"AH Ashok","year":"2017","unstructured":"Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017;22:666\u201379.","journal-title":"Mol Psychiatry"},{"key":"3657_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101537","volume":"61","author":"S Madero","year":"2026","unstructured":"Madero S, Soto-Angona O, Ona G, Sanchez-Moreno J, Vieta E. Current perspectives on psychedelic treatments in Europe. Lancet Reg Heal Eur. 2026;61:101537.","journal-title":"Lancet Reg Heal Eur"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03657-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:36:04Z","timestamp":1791826564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03657-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3657"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03657-6","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MSo has received honoraria\/has been a consultant for AbbVie, Angelini, Bausch Health, Boehringer Ingelheim, Pharmascience, Lundbeck, Otsuka, Teva. Marco Solmi holds shares of MESAS, S2M. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, AbbVie, Adamed, Adium, Alcediag, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Casen-Recordati, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Esteve, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Intra-Cellular therapies, Idorsia, Johnson & Johnson, LB pharmaceuthicals, Lundbeck, Luye Pharma, Medincell, Merck, Mitsubishi Tanabe Pharma, Newron, Novartis, Organon, Orion Corporation, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Signant Health, Sunovion, Takeda, Teva, and Viatris, outside the submitted work. MH has received honoraria\/has been a consultant for Lundbeck, Orion, Otsuka, and Rovi. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}